Parallax Volatility Advisers, L.P. Bei Gene, Ltd. Call Options Transaction History

Parallax Volatility Advisers, L.P.

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	BUY	$125.51 - $229.3 $125,510 - $229,300	1,000 New	1,000 $219,000
Q2 2018 Aug 14, 2018	SELL	$152.5 - $216.77 $12.5 Million - $17.8 Million	-82,000 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$97.41 - $177.22 $7.99 Million - $14.5 Million	82,000 New	82,000 $13.8 Million
Q4 2017 Feb 14, 2018	SELL	$79.6 - $114.73 $796,000 - $1.15 Million	-10,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$66.19 - $103.46 $661,900 - $1.03 Million	10,000	10,000 $1.04 Million

253

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $22.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.